Results 21 to 30 of about 51,582 (258)
Medical Laboratory Journal, 2022 Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by the accumulation of large amounts of fat in the hepatocytes.
Zahra Eslami +8 more
doaj
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. [PDF]
PLoS ONE, 2014 OBJECTIVE: Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40% of
Yuka Keyamura +9 more
doaj +1 more source
Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/− Mice
Translational Oncology, 2017 Atorvastatin is widely used to lower blood cholesterol and to reduce risk of cardiovascular disease–associated complications. Epidemiological investigations and preclinical studies suggest that statins such as atorvastatin have antitumor activity for ...
Ming Hong Shen +5 more
doaj +1 more source
The Korean Journal of Gastroenterology, 2021 Backgrounds/Aims: PPARγ, farnesoid X receptor (FXR) and CYP7A1 are associated with solubility of bile. This study was performed to understand a mechanism and interactions of statin-induced PPARγ, PGC-1α and HNF-4α related to the statin-induced activation
Jin Lee +7 more
doaj +1 more source
Thermodynamic and Thermomicroscopy Study of Atorvastatin Calcium-Succinic Acid Binary Mixtures
Indonesian Journal of Chemistry, 2017 Binary mixtures of pharmaceuticals significantly affect the physical and chemical properties of each component. The aim of this work was to explore the thermal behavior and solid state transformation of binary mixture of atorvastatin calcium and succinic
Yudi Wicaksono +3 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2019 The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs).
Bridget L. Morse +9 more
doaj +1 more source
Journal of Lipid Research, 2006 Statins do not always decrease coronary heart disease mortality, which was speculated based on increased serum plant sterols observed during statin treatment.
Jogchum Plat +4 more
doaj +1 more source
Mediators of Inflammation, 2021 Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitor and inhibits cholesterol synthesis. Recently, atorvastatin also showed anti-inflammatory effect in acute lung injury, ameliorating pulmonary gas-blood ...
Lan Wu +4 more
doaj +1 more source
Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
Pharmaceuticals, 2022 The interaction between statins and omega-3 fatty acids remains controversial. The aim of this phase 1 trial was to evaluate the pharmacokinetics of drug-drug interaction between atorvastatin and omega-3 fatty acids.
Jae Hoon Kim +10 more
doaj +1 more source